Emerging Treatments

Why emerging treatments matter for Asherman's

Standard hysteroscopic adhesiolysis — the surgical removal of scar tissue — is effective for many women, particularly those with mild-to-moderate disease. But it carries a real limitation: recurrence. Adhesions grow back. In moderate cases, the recurrence rate sits around 20–30%. In severe cases — women who have had multiple procedures, significant scarring, or near-total obliteration of the cavity — it can reach up to 66%.

For those women, the calculus is different. Each surgery carries risk. Each recurrence narrows the endometrium further. At a certain point, removing adhesions isn't enough — because there isn't enough healthy endometrium left to work with. What's needed isn't subtraction. It's regeneration.

That is exactly what the emerging treatments in this chapter are trying to achieve. Rather than cutting away scar tissue and hoping the endometrium recovers on its own, they aim to actively stimulate the growth of new, functional endometrial tissue. It's a fundamentally different approach — and the science behind it, particularly in the last two years, has become genuinely compelling.

Knowing what's possible also matters emotionally. When I was in the thick of treatment — cycling through surgeries, watching my periods come and go and come back lighter — the thing I needed most was evidence that the trajectory was moving in the right direction. That help wasn't frozen at the current standard of care. That somewhere, people were working on something better.

Stem cell therapy — the most promising frontier

If you have been following Asherman's research at all, you will have seen stem cell therapy mentioned. It has been discussed for over a decade. What has changed in 2025 is that we now have human trial data — not just animal models, not just case reports — showing meaningful, measurable results.

What the 2025 trials found

A Phase 1/2 trial published in Nature Communications (Carlos Simon Foundation, 2025) administered autologous CD133+ bone marrow-derived stem cells directly into the uterine cavity of women with refractory Asherman's — women who had failed conventional treatment. The results were significant across multiple outcome measures: improvements in endometrial structure and function confirmed by ultrasound, hysteroscopy, and transcriptomic analysis. The treatment was well tolerated with no serious adverse events. Some participants became pregnant and delivered.

A 2025 systematic review and meta-analysis (published in PMC) pooled data from 12 studies encompassing 137 women with refractory Asherman's who had not responded to conventional therapy. The findings were striking:

Yale Medicine is also running an ongoing clinical trial studying Bone Marrow Derived Stem Cells Mobilisation for Asherman's syndrome, atrophic endometrium, and recurrent implantation failure — which means this is not a fringe research direction. It is being pursued at major academic centres.

How it works

Several types of stem cells are being studied, including bone marrow-derived CD133+ cells, mesenchymal stem cells (MSCs), and endometrial stem cells. The proposed mechanisms are twofold: stem cells may differentiate into endometrial cell types directly, and they appear to promote regeneration through paracrine signalling — releasing growth factors that stimulate the surrounding tissue to repair itself, even when the stem cells themselves do not persist long-term.

In autologous approaches (where the patient's own cells are used), bone marrow is harvested from the patient, stem cells are isolated and concentrated, and then administered directly into the uterine cavity — sometimes combined with hysteroscopic adhesiolysis, sometimes as a standalone intervention. Timing and optimal route of administration are still being refined.

Honest caveats

I want to be clear about what we do and don't know. Stem cell therapy for Asherman's is still largely experimental. The trials are small. The methodologies vary across studies, making comparison difficult. It is not available at most hospitals, and where it is available, costs are significant. The optimal cell type, dose, timing, and delivery method remain under investigation.

The data is genuinely exciting. It is also preliminary. Both of those things are true at once, and I think it's important to hold them together — to feel the hope without building a recovery plan entirely around a treatment that may not yet be accessible to you. But knowing it exists? That matters. It changes what questions you can ask.

Platelet-Rich Plasma (PRP)

PRP is worth understanding in detail — not because it has the drama of stem cell therapy, but because it is more immediately accessible. Many specialist fertility clinics are already offering it, and it is worth knowing whether you might be a candidate.

What it is

Platelet-Rich Plasma is made from your own blood. A blood draw is taken, centrifuged at high speed to concentrate the platelets, and the resulting platelet-rich plasma is then infused into the uterine cavity. The procedure is relatively simple and uses your own biology — which means immunological risk is minimal.

Why it's being used for Asherman's

Platelets are, among other things, growth factor delivery vehicles. When they activate at a site of injury, they release a range of growth factors — including VEGF (vascular endothelial growth factor), EGF (epidermal growth factor), PDGF (platelet-derived growth factor), and TGF-β (transforming growth factor beta) — that stimulate tissue repair, cell proliferation, and angiogenesis (new blood vessel formation). The idea is that delivering a concentrated bolus of these factors directly into the uterine cavity may stimulate endometrial regeneration and improve blood flow to scarred tissue.

The Cleveland Clinic notes that researchers are studying PRP as a treatment for Asherman's syndrome and thin endometrium. Case series and small studies have shown improvements in endometrial thickness and some pregnancies in women who had previously failed conventional treatment. Larger, randomised controlled trials are still needed — but the biological rationale is sound and the early data is encouraging.

If you are at a stage where you have been told your endometrial lining is thin and unresponsive despite oestrogen supplementation, PRP is a reasonable question to raise with a specialist. Ask specifically: "Am I a candidate for intrauterine PRP infusion? What outcomes have you seen in similar cases?"

Granulocyte Colony-Stimulating Factor (G-CSF)

G-CSF is a growth factor that stimulates the production and mobilisation of stem cells from bone marrow. It's been used in oncology for decades to help patients recover blood cell production after chemotherapy — and researchers have been exploring whether its stem cell-mobilising properties might also promote endometrial regeneration.

How it's being used

In the context of Asherman's and thin endometrium, G-CSF is typically administered by intrauterine infusion — the same route as PRP. The hypothesis is that by mobilising the body's own stem cells and directing growth-promoting signals toward the uterus, G-CSF may stimulate the growth of new endometrial tissue.

A number of studies have shown improvements in endometrial thickness in women with a thin lining who haven't responded to oestrogen alone. The evidence specifically for Asherman's-related scarring is thinner than for PRP — most data is in the context of thin endometrium without significant adhesions — but it is being actively explored. Some clinics use it in combination with PRP or alongside hysteroscopic treatment.

G-CSF is not yet standard of care for Asherman's, and evidence remains early-stage. It's worth asking about if conventional hormone protocols have not improved your endometrial thickness over multiple monitored cycles.

Uterine transplant

I want to include this because it deserves to be known — not because it's a likely path for most women, but because for those who have exhausted all other options, the fact that it exists matters enormously.

Uterine transplantation is no longer theoretical. The first live births from transplanted uteri occurred in Sweden, and subsequently in the United States. Programmes now exist at a small number of specialist centres. The procedure involves transplanting a uterus from a living or deceased donor, allowing the recipient to carry a pregnancy, and then typically removing the transplanted uterus once childbearing is complete (to end immunosuppression).

The surgery is major. Immunosuppression is required throughout the pregnancy. Donor availability is limited. This is an option for a very small number of women — those for whom the endometrium is irreversibly damaged and for whom all regenerative approaches have failed.

But it is an option. And knowing it exists changes the emotional calculus of a worst-case scenario. There is no ceiling. There is always something further out on the horizon — even if you hope you never need it.

Hormone protocols in development

Not every emerging approach involves a new drug or a complex procedure. Some of the most promising developments are refinements of what we already have — using hormones we know well, in smarter ways.

High-dose oestrogen combined with growth factors is being explored to more aggressively stimulate endometrial growth in women with thin, unresponsive linings. The rationale is that standard doses, optimised for a normal endometrium, may be insufficient for a severely scarred one — and that layering in growth factor support alongside oestrogen may produce a synergistic effect.

Sequential progesterone timing optimisation is another area of active interest. When progesterone is introduced relative to oestrogen priming appears to influence the endometrium's receptivity window, and fine-tuning this timing — using transcriptomic testing to identify each individual's optimal implantation window — may improve outcomes in Asherman's-affected uteri.

Gonadotropins have been used in some protocols to stimulate a more robust endometrial response, though evidence in the Asherman's context specifically remains limited. These are refinements of the existing pharmacological toolkit — not revolutionary, but potentially meaningful for the right patient.

These approaches are worth asking about if you have had multiple cycles with disappointing endometrial thickness despite conventional oestrogen supplementation. The question to raise: "Are there more aggressive hormonal protocols, or protocols that combine oestrogen with growth factor support, that might be appropriate in my case?"

How to access emerging treatments

Knowing this research exists is step one. Understanding how to actually reach it is step two — and this is where I want to give you something concrete and actionable.

Start with your specialist

The simplest first step is to raise these treatments directly with your gynaecologist or reproductive endocrinologist. A specific, informed question lands differently than a general request for "more options." Try:

• "Am I a candidate for intrauterine PRP infusion, given my endometrial history?"
• "What is your experience with G-CSF for thin endometrium or Asherman's-related scarring?"
• "Are there any stem cell trials you're aware of that might be relevant to my case?"

A specialist who is current in their field will have an opinion on these. A specialist who dismisses them entirely without explanation is someone worth getting a second opinion from.

Search ClinicalTrials.gov

ClinicalTrials.gov is the US National Institutes of Health registry of clinical trials worldwide. You can search by condition and location. For Asherman's, try searching for:

• "Asherman's syndrome" — broad search for all trials
• "intrauterine adhesions" — the clinical term, may return different results
• "endometrial regeneration" — may capture relevant trials not specifically tagged for Asherman's

When evaluating a trial: Phase 1 trials are primarily about safety; Phase 2 about early efficacy; Phase 3 about definitive efficacy. Check the eligibility criteria carefully — many trials specify disease severity, prior treatment history, or other requirements. If you're uncertain about eligibility, contacting the trial coordinator directly is reasonable; they are used to these enquiries.

Private clinics offering PRP

PRP is increasingly available at specialist fertility clinics without requiring trial enrolment. If you are considering this route, ask the clinic directly:

• "How many intrauterine PRP procedures have you performed for Asherman's-related thin endometrium?"
• "What outcomes have you seen in patients with a similar history to mine?"
• "What protocol do you use — timing relative to my cycle, number of infusions, combination with any other treatment?"

A clinic that can answer these questions specifically, with real numbers, is one worth trusting more than one that speaks only in generalised optimism.

Endometrial testing — ERA, EMMA & ALICE

If you are going through IVF and your embryo transfers keep failing despite good-quality embryos and adequate lining, there is a generation of diagnostic tests that may explain why. These are genuinely cutting-edge tools, and they are particularly relevant for women with Asherman's history.

ERA — your personal implantation window

In a standard IVF protocol, everyone gets progesterone for the same number of days before embryo transfer. But women with Asherman's history are known to have a higher incidence of a displaced window of implantation — meaning their optimal day for transfer is different from the standard protocol. The ERA test analyses gene expression in a small endometrial biopsy to identify your personal optimal window, accurate to the hour in newer RNA-sequencing versions.

A 2024 study in Frontiers in Endocrinology found that hourly-precision endometrial receptivity testing improved clinical pregnancy rates from 38.6% to 54.8% in patients with recurrent implantation failure when transfer was timed to the individual window. For patients whose window was found to be displaced and timing was corrected, rates reached 58.6% versus 38.6% with standard protocol.

EMMA & ALICE — the uterine environment

EMMA tests the microbial balance of the uterine cavity. A healthy endometrial microbiome is dominated by Lactobacillus species — disruption (dysbiosis) is associated with implantation failure. For women with Asherman's, who have a history of uterine trauma, repeated procedures, and post-surgical treatments, this environment is often compromised.

ALICE detects pathogenic bacteria causing chronic endometritis — a silent, persistent inflammation of the uterine lining. In women with recurrent implantation failure, chronic endometritis has been found in up to 66% of cases. Treatment with targeted antibiotics, followed by a subsequent transfer, has been associated with pregnancy rates of 65.2% versus 33.0% and live birth rates of 60.8% versus 13.3% in treated versus untreated cases.

Advanced IVF protocols for Asherman's women

The standard IVF protocol was not designed with Asherman's in mind. But there is a growing body of research — much of it from 2024–2026 — shaping what an optimised protocol looks like. If previous cycles have failed, or you are about to start, this is the conversation to have with your specialist.

Freeze-all strategy

For women with thin endometrium, frozen embryo transfer (FET) yields dramatically better results than fresh transfer: live birth rates ~30.6% versus 18.4%, clinical pregnancy rates 40% versus 26.4% in multiple studies. The reason — a freeze-all strategy allows the ovaries to rest from stimulation, giving the endometrium a full cycle to respond to oestrogen priming without suppressive effects from the stimulation phase. For Asherman's women, this should be the default approach, not a fallback.

GnRHa downregulation before FET

A 2025 study in the International Journal of Women's Health found that for Asherman's patients, adding GnRH agonist downregulation before frozen embryo transfer significantly improved clinical pregnancy rates (OR 0.218) and live birth rates (OR 0.362) compared to standard HRT alone. The same study found that endometrial pattern — specifically the trilaminar (triple-line) appearance — was a stronger predictor of success than thickness alone. If your clinic is using thickness as the sole go/no-go criterion, ask about trilaminar assessment too.

Vaginal sildenafil for thin lining

Vaginal sildenafil improves uterine artery blood flow, creating better conditions for endometrial proliferation. Multiple studies have found it significantly improves endometrial thickness and clinical pregnancy rates in FET cycles. A 2021 study specifically in women post-IUA resection found improved outcomes with sildenafil in the follicular phase. If your lining consistently fails to reach adequate thickness despite oral oestrogen, vaginal sildenafil is a well-studied and accessible next step.

G-CSF for transfer-eligible lining

Intrauterine G-CSF (granulocyte colony-stimulating factor) reliably increases endometrial thickness in treatment-resistant thin endometrium — restoring transfer eligibility in cycles that would otherwise be cancelled. A 2026 review in Life describes it as a "conditioning agent" rather than a proliferative treatment: it addresses vascular and stromal dysfunction without causing abnormal angiogenesis. For women whose cycles are cancelled due to lining failure, G-CSF can be the intervention that allows transfer to proceed.